LSTA Lisata Therapeutics Inc.: רווח למניה אחת ב-12 החודשים האחרונים

Lisata Therapeutics (LSTA) develops systems for the deep penetration of drugs into tumor tissues. The current EPS YoY TTM trajectory illustrates that success depends on the CendR platform and pancreatic cancer trials, where the parameter value equals 11.30. The company's innovations alter the neoplastic environment, rendering tumors vulnerable. Currently, there is no revenue, and potential income is tied to future contracts with pharmaceutical industry behemoths.
Lisata Therapeutics - פילוחים אנליטיים ומדדי מפתח (LSTA)

Year-over-year (YoY) EPS growth (TTM) measures the percentage change in net income per share over a rolling twelve-month period, allowing investors to filter out short-term noise and identify the true trajectory of profitability. By analyzing the current EPS YoY TTM dynamics, one can assess how the optimization of complex medical logistics for chemotherapy drugs converts into financial results for Lisata Therapeutics (LSTA), preventing the unjustified freezing of investment capital.